Business Wire

VA-DXC-TECHNOLOGY

2.1.2020 10:02:09 CET | Business Wire | Press release

Share
New Shared Mobility Concept, Luxoft HALO, Introduces a Revolutionary Digital, Consumer-Grade In-Vehicle Experience

Luxoft , a DXC Technology Company (NYSE: DXC), today in collaboration with LG Electronics, Amazon and Mapbox unveiled Luxoft HALO, the company’s latest shared mobility concept featuring a revolutionary digital, consumer-grade in-vehicle experience. Luxoft HALO will be formally debuted at CES® 2020, Jan. 7-10, 2020, Las Vegas, NV.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200102005099/en/

At home, consumers expect their digital experiences to be simple, convenient and accessible at any time across a range of devices. Increasingly, consumers also expect access to their favorite content and services, in the vehicle and on the go.

Luxoft HALO shared mobility concept demonstrates how all consumers’ mobility needs can be seamlessly integrated with their personal digital lifestyle.

”Together with our key partners, we can now deliver a complete, highly personalized and intelligent in-vehicle consumer-grade experience, powered by webOS Auto, the platform for shared and intelligent mobility,” said Vildan Hasanbegovic, director of partnerships and head of marketing at Luxoft Automotive. ”It’s an open platform that delivers, with exceptional quality, an existing ecosystem of intelligent services and dynamic content — from in-vehicle infotainment to connected video streaming services and more — that is increasingly becoming an essential part of consumers‘ personal digital lifestyles.”

Luxoft can already deploy webOS Auto to large-scale series production systems, including:

  • Rear Seat Entertainment (RSE) for traditional needs;
  • Rear Seat Entertainment (RSE) with ride-hailing mode;
  • Cabin display for ride-hailing systems; and
  • Center stack display for ride-hailing systems.

Partner Innovations Showcased in Luxoft HALO

LG Electronics and webOS Auto

webOS Auto is an open and ideal platform for shared and intelligent mobility. webOS Auto provides features, and functionality, and incorporates all essential components such as multimedia processing, multi-display control, connectivity, security, offering improved comfort and convenience to passengers.

Alexa Auto

Alexa already helps you simplify and organize your life at home – now you can take her with you on the go with Alexa Auto. Alexa can help you play music, get directions, place calls, listen to audiobooks, control your smart home, and more, with just your voice – so you can keep your hands on the wheel and eyes on the road. Alexa is already available in dozens of vehicles from leading automakers, and Amazon has released services like the Alexa Auto SDK that make it easy for automakers and suppliers to integrate Alexa directly into their infotainment system. To learn more, visit amazon.com/alexa-auto/ .

Mapbox

Mapbox is a live location data platform powering maps and navigation experiences for mobile, web, gaming, and automotive. Mapbox maintains SDKs for developers building for webOS Auto, Android, iOS, Unity 3D, and web, and APIs for rendering maps and performing spatial functions. Every month, over 150,000 developers build with Mapbox. Over 45,000 mobile apps are powered by Mapbox SDKs. Applications and platforms built by developers using Mapbox reach more than 600 million monthly active users.

Luxoft at CES® 2020

Visit Luxoft at CES for a personal, hands-on experience of Luxoft HALO and to experience the future of shared and intelligent mobility; booth #6928, North Hall, Tech East, Las Vegas Convention and World Trade Center.

About Luxoft

Luxoft, a DXC Technology Company, (NYSE: DXC), is a digital strategy and software engineering firm providing bespoke technology solutions that drive business change for customers the world over. Luxoft uses technology to enable business transformation, enhance customer experiences, and boost operational efficiency through its strategy, consulting, and engineering services. Luxoft combines a unique blend of engineering excellence and deep industry expertise, specializing in automotive, financial services, travel and hospitality, healthcare, life sciences, media and telecommunications. For more information, please visit www.luxoft.com .

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .

All information set out in the materials is provided in good faith but does not form part of or constitute an offer or contract. Statements, figures, plans, views and representations are for presentation purposes and indicative only. Luxoft has made reasonable efforts to include accurate information, wherever possible. However, Luxoft makes no warranties or representations, expressed or implied, as to the completeness of the information provided. Luxoft will not be liable for any damages, including but not limited to special or consequential damages, that result from the use of, or the inability to use, the material contained in these materials .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye